130658-65-0

Usage

Uses

Used in Pharmaceutical Industry:
4-HYDROXY-1-(PYRIDIN-4-YL)-PIPERIDINE is used as a synthetic intermediate for the development of new pharmaceuticals. Its structural features allow it to be incorporated into more complex molecules, potentially leading to the creation of novel drugs with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-HYDROXY-1-(PYRIDIN-4-YL)-PIPERIDINE is utilized as a precursor in the synthesis of agrochemicals. Its chemical properties make it suitable for the development of new pesticides or other agricultural chemicals that can enhance crop protection and yield.
Used in Drug Discovery and Development:
4-HYDROXY-1-(PYRIDIN-4-YL)-PIPERIDINE is employed as a potential candidate in drug discovery and development due to its biological activity. Researchers explore its interactions with biological targets to identify potential therapeutic applications, such as treating diseases or managing conditions that currently lack effective treatments.
Used in Research Applications:
4-HYDROXY-1-(PYRIDIN-4-YL)-PIPERIDINE's unique structure and properties make it a valuable tool in various research applications. Scientists use 4-HYDROXY-1-(PYRIDIN-4-YL)-PIPERIDINE to study molecular interactions, develop new synthetic methods, and understand the underlying mechanisms of biological processes.

InChI:InChI=1/C10H14N2O/c13-10-3-7-12(8-4-10)9-1-5-11-6-2-9/h1-2,5-6,10,13H,3-4,7-8H2

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 7379-35-3 4-chlorpyridine hydrochloride 
• 1120-87-2 4-bromopyridin 
• 626-61-9 4-Chloropyridine 

Downstream Products

• 194853-83-3 3-[1-(pyridin-4-yl)piperidin-4-yloxy]aniline 
• 219492-89-4 2-[1-(pyridin-4-yl)piperidin-4-ylaminocarbonyl]amino-nitrobenzene 
• 219492-90-7 1-(2-amino-phenyl)-3-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-urea 
• 284030-16-6 (2-amino-phenyl)-carbamic acid 3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl ester 
• 187084-44-2 3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylamine 

Relevant academic research and scientific papers

Sulfonamide derivatives, processes for producing the same and utilization thereof

The present invention is to provide a compound or a salt thereof represented by the formula: wherein R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, X′ is an optionally substituted alkylene chain, Y is an optionally substituted divalent cyclic group, X is a chemical bond or an optionally substituted alkylene chain, and Z is (1) an optionally substituted amino group, (2) an optionally substituted imidoyl group or (3) an optionally substituted nitrogen-containing heterocyclic group, or a pro-drug thereof, which have activated coagulation factor X inhibitory activity and which are useful as anti-coagulants.

Antithrombotic agents

This application relates to a compound of formula (I), a pharmaceutically acceptable salt of the compound, or a prodrug thereof, as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Heterocyclic compounds useful as pharmaceutical agents

Compounds of formula (I) in which all variables are defined in the description and their salts inhibit the enzyme oxido squalene cyclase and are useful in treating hypercholesterolemia and also as anti-fungal agents. Processes for their preparation are also described together with their use in medicine.

Heterocyclic compouds

A compound of the general formula wherein: n is 0 or 1; M1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.

Heterocyclic derivatives

Compounds of formula I STR1 and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R13, M2, X1, Z1, Z1a, X2 and A1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Novel intermediates are also disclosed.

Heterocyclic derivatives

Compounds of formula I STR1 and metabolically labile esters and amides thereof, and pharmaceutically acceptable salts thereof, in which R13, M2, X1, Z1, Z1a, X2 and A1 have the meanings given in the specification. The compounds are useful as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa. Intermediates are also disclosed.

Pyridine compounds which are useful as anti-arrhythmic agents

A series of novel aryloxyalkylamino- and arylaminoalkylamino-pyridine and imidazole compounds have been prepared, including their pharmaceutically acceptable salts, wherein the aryl moiety is further substituted by a sulphamoyl or sulphonylamino group or